Dicot Pharma AB
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
Dicot Pharma AB (KN0) - Total Assets
Latest total assets as of June 2025: €118.30 Million EUR
Based on the latest financial reports, Dicot Pharma AB (KN0) holds total assets worth €118.30 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dicot Pharma AB - Total Assets Trend (2021–2024)
This chart illustrates how Dicot Pharma AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dicot Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Dicot Pharma AB's total assets of €118.30 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 91.8% |
| Accounts Receivable | €4.80 Million | 3.9% |
| Inventory | €5.38 Million | 4.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Dicot Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dicot Pharma AB's current assets represent 100.0% of total assets in 2024, an increase from 99.9% in 2021.
- Cash Position: Cash and equivalents constituted 91.8% of total assets in 2024, down from 95.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 4.4% of total assets.
Dicot Pharma AB Competitors by Total Assets
Key competitors of Dicot Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Dicot Pharma AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Dicot Pharma AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Dicot Pharma AB is currently not profitable relative to its asset base.
Dicot Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.86 | 2.67 | 2.67 |
| Quick Ratio | 9.32 | 1.98 | 1.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €106.30 Million | € 17.45 Million | € 17.45 Million |
Dicot Pharma AB - Advanced Valuation Insights
This section examines the relationship between Dicot Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 130.8% |
| Total Assets | €123.62 Million |
| Market Capitalization | $47.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dicot Pharma AB's assets below their book value (0.39 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dicot Pharma AB's assets grew by 130.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dicot Pharma AB (2021–2024)
The table below shows the annual total assets of Dicot Pharma AB from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €123.62 Million | +130.83% |
| 2023-12-31 | €53.55 Million | +332.90% |
| 2022-12-31 | €12.37 Million | -61.06% |
| 2021-12-31 | €31.77 Million | -- |